- Home
- NUWE vs VRAX Comparison
NUWE vs VRAX Comparison
Compare NUWE & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- VRAX
- Stock Information
- Founded
- NUWE 1999
- VRAX 2013
- Country
- NUWE United States
- VRAX United Kingdom
- Employees
- NUWE N/A
- VRAX N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NUWE Health Care
- VRAX Health Care
- Exchange
- NUWE Nasdaq
- VRAX Nasdaq
- Market Cap
- NUWE 3.9M
- VRAX 4.4M
- IPO Year
- NUWE N/A
- VRAX 2022
- Fundamental
- Price
- NUWE $3.77
- VRAX $0.62
- Analyst Decision
- NUWE
- VRAX Strong Buy
- Analyst Count
- NUWE 0
- VRAX 1
- Target Price
- NUWE N/A
- VRAX $3.00
- AVG Volume (30 Days)
- NUWE 192.1K
- VRAX 1.6M
- Earning Date
- NUWE 11-10-2025
- VRAX 01-01-0001
- Dividend Yield
- NUWE N/A
- VRAX N/A
- EPS Growth
- NUWE N/A
- VRAX N/A
- EPS
- NUWE N/A
- VRAX N/A
- Revenue
- NUWE $8,318,000.00
- VRAX $6,331.00
- Revenue This Year
- NUWE $6.53
- VRAX $217,274.83
- Revenue Next Year
- NUWE $51.63
- VRAX N/A
- P/E Ratio
- NUWE N/A
- VRAX N/A
- Revenue Growth
- NUWE N/A
- VRAX N/A
- 52 Week Low
- NUWE $3.74
- VRAX $0.52
- 52 Week High
- NUWE $175.98
- VRAX $3.62
- Technical
- Relative Strength Index (RSI)
- NUWE 29.64
- VRAX 42.86
- Support Level
- NUWE $3.74
- VRAX $0.59
- Resistance Level
- NUWE $5.23
- VRAX $0.70
- Average True Range (ATR)
- NUWE 0.35
- VRAX 0.05
- MACD
- NUWE 0.12
- VRAX 0.01
- Stochastic Oscillator
- NUWE 7.59
- VRAX 56.29
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).